Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
Advances in the treatment of primary central nervous system lymphoma
J. Jin, L. Cao, J. Wei, Ping Liu
School of Population and Global Health
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Advances in the treatment of primary central nervous system lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Primary Central Nervous System Lymphoma
75%
Overall Survival
25%
Neurotoxicity
25%
High Dose Chemotherapy
25%
Temozolomide
25%
New Drug
12%
Glucocorticoid
12%
Recurrent Disease
12%
Methotrexate
12%
Cytarabine
12%
Progression Free Survival
12%
Rare Disease
12%
Procarbazine
12%
Medicine and Dentistry
Primary Central Nervous System Lymphoma
75%
Radiation Therapy
37%
Overall Survival
25%
Neurotoxicity
25%
Temozolomide
25%
Recurrent Disease
12%
Biopsy
12%
Drug Megadose
12%
Glucocorticoid
12%
Rare Disease
12%
Prophylaxis
12%
Methotrexate
12%
New Drug
12%
Elderly Patient
12%
Progression Free Survival
12%
Cerebrospinal Fluid
12%
Whole Brain Radiotherapy
12%
Cytarabine
12%
Procarbazine
12%
Autologous Stem Cell Transplantation
12%
Agricultural and Biological Sciences
Central Nervous System
100%
Neurotoxicity
33%
Glucocorticoid
16%
New Drugs
16%
Cerebrospinal Fluid
16%
Autologous Stem Cell Transplantation
16%